It clarifies the core differences between SGLT2 inhibitors and GLP-1 receptor agonists, covering their mechanisms, clinical advantages and representative products. It highlights Orforglipron, a breakthrough oral small-molecule GLP-1 agonist.
Master regulatory submission for pharmaceutical intermediates with DMF/CEP documentation best practices. Fix common deficiencies, align with FDA/EDQM guidelines, and streamline review processes.
This article breaks down 4 core risks with authoritative industry data, and shares full-process, FDA & ICH-aligned solutions to reduce accidents, improve yields and ensure compliance.
This article breaks down the 4 most costly mistakes — including incomplete documentation and ignored scalability — with verified industry data and real cases.
End-to-end supply chain for anti-diabetic intermediates. Covering DPP-4, SGLT-2 inhibitors & GPR40 agonists. Stable, compliant, scalable.
Drawing from on-the-ground experience in China’s top pharma clusters, this guide cuts through the jargon to reveal when to partner for complex innovation and when to buy from the workhorses of mature production.
This case study, based on publicly available academic literature and patents, focuses on the application of synthetic route optimization in improving the yield and purity of Active Pharmaceutical Ingredients (APIs).
Learn how to manage hazardous reactions during intermediate synthesis with risk assessment, process control, and safety management strategies.
Manufacturer and supplier of pharmaceutical APIs and intermediates. Contact us for technical support and sourcing solutions.
